Abstract
Zoledronic acid is a newly FDA-approved bisphosphonate for the treatment of hypercalcemia of malignancy. Although the safety and efficacy of this drug in treating hypercalcemia associated with hyperparathyroidism have not yet been established in clinically controlled trials, its off-label use is not uncommon. We describe a patient with primary hyperparathyroidism treated with zoledronic acid who developed severe postoperative hypocalcemia. A 64-yr-old woman was admitted with severe hypercalcemia. She was treated with rehydration, calcitonin, methylprednisolone, furosemide as well as 4 mg/day of zoledronic acid for two consecutive days. Primary hyperparathyroidism caused by a right inferior parathyroid lesion was diagnosed. While awaiting surgery, she continued furosemide, methylprednisolone and hydration: after one week, serum calcium had fallen to such a low level that a short-term calcium carbonate supplementation was required. Three weeks after admission, the patient underwent selective right inferior parathyroidectomy, followed by reduction of PTH. During the postoperative period the patient presented severe hypocalcemia resistant to the usual treatment. Serum calcium levels returned to normal three months after surgery. The severity of hypocalcemia and the resistance to conventional treatments suggest that the effect of hungry bone syndrome could be worse in patients treated with bisphosphonates in the preoperative phase.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bilezikian JP, Silverberg SJ, 2000 Clinical spectrum of primary hyperparathyroidism. Rev Endocr Metab Disord 1: 237–245.
Makras P, Papapoulos SE, 2009 Medical treatment of hypercalcaemia. Hormones (Athens) 8: 83–95.
Brasier AR, Nussbaum SR, 1988 Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 84: 654–60.
Benford HL, Frith JC, Auriola S, Mönkkönen J, Rogers MJ, 1999 Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131–140.
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ, 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581–589.
Bilston LE, Little DG, Smith NC, Williams P, Briody J, 2002 Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech (Bristol, Avon) 17: 716–718.
Silverberg SJ, 2007 Vitamin D deficiency and primary hyperparathyroidism. J Bone Min Res 22: Suppl 2: V100–104.
Lee IT, Sheu WH, Tu ST, Kuo SW, Pei D, 2006 Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. J Bone Min Metab 24: 255–258.
Graal MB, Wolffenbuttel BH, 1998 Consequences of long-term hyperparathyroidism. Neth J Med 53: 37–42.
Whitson HE, Lobaugh B, Lyles KW, 2006 Severe hypocalcemia following bisphosphonate treatment in a patient with Paget’s disease of bone. Bone 39: 954–958.
Lazar ES, Stankus N, 2007 Cinacalcet-induced hungry bone syndrome. Semin Dial 20: 83–85.
Yavropoulou MP, Kotsa K, Gotzamani-Psarrakou A, et al, 2010 Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones (Athens) 9: 274–278.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Corsello, S.M., Paragliola, R.M., Locantore, P. et al. Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid. Hormones 9, 338–342 (2010). https://doi.org/10.14310/horm.2002.1286
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1286